HongKong:1167

Jacobio Announces FDA Approves IND Application to Develop KRAS G12C Inhibitor

BEIJING and SHANGHAI and BOSTON, May 2, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) has announced  the U.S. Food and Drug Administration (FDA) has approved company's Investigational New Drug (IND) application to develop a KRAS G12C inhibitor. IND application to the National Medical Pro...

2021-05-03 09:30 4703

Jacobio Pharma Announces CNY486 Million Revenue for 2020 Annual Results

BEIJING and BOSTON, March 29, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) announced its first annual results after itsHong Kong listing. By the end ofDecember 31, 2020, its annual revenue was 486 million yuan and R&D expenses exceeded230 million yuan and increased 66% compared to 2019....

2021-03-29 13:11 3916
123

Week's Top Stories